SCHEMBL7972964

SCHEMBL7972964

Cn1nc(-c2ccccc2O)c(O)c1-c1nc2ccc(CN)cc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 4/20 0.44
F10 P00742 4/20 0.44
PRSS1 P07477 4/20 0.44
PLG P00747 3/20 0.44
PLAU P00749 3/20 0.44
PLAT P00750 2/20 0.44
PRSS2 P07478 2/20 0.44
PRSS3 P35030 2/20 0.44
HPN P05981 1/20 0.44
F7 P08709 2/20 0.43
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDR P35968 1/20 0.39
GSK3B P49841 1/20 0.39
F3 P13726 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10139913 0.87 F9 (0.43) F2F10PRSS1PLGPLAU
SCHEMBL7970846 0.84 CHEK2 (0.44) NPC1RAB9ASMN1; SMN2KDRGSK3B
SCHEMBL7970550 0.83 F9 (0.46) F10KDRGSK3BNPBWR1PTGDR2
SCHEMBL10140088 0.82 CHEK2 (0.54) F2F10PRSS1PLGPLAU
SCHEMBL7969006 0.82 NPBWR1 (0.42) F10GSK3BCBFBNPBWR1PTGDR2
SCHEMBL16258935 0.82 CBFB (0.43) F10GSK3BCBFBNPBWR1PTGDR2
SCHEMBL7971481 0.81 HIF1A (0.46) KDM4ENPC1ALDH1A1GAAMAPT
SCHEMBL7969075 0.81 PTGDR2 (0.44) F10GSK3BNPBWR1PTGDR2
SCHEMBL7959240 0.80 NPC1 (0.44) F10KDM4ENPC1ALDH1A1GAA
SCHEMBL10140025 0.79 MAPT (0.45) KDM4ENPC1ALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2805939-B1 Heterocyclic compounds as factor IXA inhibitors. MERCK SHARP & DOHME (US) 2018-06-27 EP disclosed
EP-2805939-A1 Heterocyclic compounds as factor IXA inhibitors. Merck Sharp & Dohme Corp. (US) 2014-11-26 EP disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
WO-2009143039-A2 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS SCHERING CORPORATION (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 F2 12/4885F10 11/4885PRSS1 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.